Effect of a novel antineoplastic drug olipifat on antitumor immunity in mice.
Olipifat is an antineoplastic drug containing pyrophosphate and a product of special lignin processing. Donor C57Bl/6J mice with syngeneic B16 melanoma received a single 5-day course of olipifat. Effect of olipifat on antitumor resistance was evaluated by local neutralization test [3]. In animals with rapid melanoma growth, splenic cells from intact donors stimulated tumor growth. Olipifat abolished this growth-stimulating effect of splenocytes. In animals with slow melanoma growth, splenocytes had no effect on the growth of melanoma or Lewis lung cancer. In this case, splenocytes from olipifat-treated donors completely arrested the growth of melanoma B16 and decelerated the growth of Lewis lung carcinoma.
Bukhman
V M
VM
G. F. Gauze Institute for New Antibiotics, Russian Academy of Medical Sciences, Moscow.
Bodyagin
D A
DA
Pereverzeva
E R
ER
Treshchalin
I D
ID
Isakova
E V
EV
Krivosheev
S E
SE
Reztsova
V V
VV
Filov
V A
VA
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018827:Carcinoma, Lewis Lung; D008031:Lignin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D008198:Lymph Nodes / Q000187:drug effects; D008207:Lymphatic Metastasis; D008546:Melanoma, Experimental; D051379:Mice; D008810:Mice, Inbred C57BL; D013154:Spleen / Q000187:drug effects; D013950:Thymus Gland / Q000187:drug effects; D013997:Time Factors
D000970:Antineoplastic Agents; C413426:olipifat; D008031:Lignin